Dr Baojiang Liu, MD is an expert in Oncology at Peking University Cancer Hospital (China). Baojiang Liu has authored 46 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 307 (community average: 125). How the SLR is computed.

LeadR Profile

Dr Baojiang Liu, MD Peking University Cancer Hospital China
307 ScienceLeadR Reputation 307
Network Map

Oncology

Subspecialties: Biochemistry - Pharmacy - Hepatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2013 - 2026
Source: PubMed

Peking University Cancer Hospital

2019 - 2026

Peking University

2019 - 2026

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 46

Citations

Citations: 541 1st author: 12 Last author: 23 Unique author: 0


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
A retrospective analysis of TACE-based multimodal liver-directed therapy for unresectable gastroenteropancreatic neuroendocrine carcinoma with liver metastases.
PMID 42997711 — mortality, safety, progression-free survival, liver, drug-related side effects and adverse reactions, neoplasm metastasis, therapeutics, prognosis, carcinoma, neuroendocrine
Transl Cancer Res20260
Efficacy and safety of drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in unresectable gastric cancer with liver metastasis.
PMID 42254872 — safety, progression-free survival, pain, pharmaceutical preparations, neoplasms, drug therapy, liver, neoplasm metastasis, therapeutics, stomach neoplasms, chemotherapy
Ther Adv Med Oncol20260
Combining partial splenic embolization with hepatic artery infusion chemotherapy in the management of chemotherapy-induced hypersplenism in patients with colorectal cancer liver metastases.
PMID 42241173 — neoplasms, hepatic artery, drug therapy, arteries, liver, liver neoplasms, neoplasm metastasis, hypersplenism, therapeutics, colorectal neoplasms, thrombocytopenia, chemotherapy
J Cancer Res Ther20260
Sodium alginate-integrated MXene sediment /Fe₃O₄ evaporator for salt-resistant and efficient continuous water evaporation.
PMID 40975356 — alginates, solutions, seawater, work
Int J Biol Macromol20250
Amylopectin-phytic acid-based hyperstretchable hydrogel with 30-minute self-healing and high adhesion for human motion monitoring.
PMID 40953618 — tissue adhesions, hydrogel, polyethylene glycol dimethacrylate, hydrogels, phytic acid, polysaccharides, work, amylopectin
Int J Biol Macromol20250

Clinical Studies 2

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 2 1

By status:

Recruiting 1
Unknown 1

By type:

Interventional 1
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
The Comparison Between HepaSphere Drug eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
NCT05862181 — carcinoma, hepatocellular, safety, pharmaceutical preparations, drug therapy, chemotherapy, carcinoma
N/ARecruiting2023

LeadR Networks

Main global connection map